- Home
- VOXR vs LXEO Comparison
VOXR vs LXEO Comparison
Compare VOXR & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VOXR
- LXEO
- Stock Information
- Founded
- VOXR 2014
- LXEO 2017
- Country
- VOXR Canada
- LXEO United States
- Employees
- VOXR N/A
- LXEO N/A
- Industry
- VOXR Precious Metals
- LXEO
- Sector
- VOXR Basic Materials
- LXEO
- Exchange
- VOXR Nasdaq
- LXEO Nasdaq
- Market Cap
- VOXR 128.1M
- LXEO 140.6M
- IPO Year
- VOXR N/A
- LXEO 2023
- Fundamental
- Price
- VOXR $2.42
- LXEO $2.70
- Analyst Decision
- VOXR
- LXEO Strong Buy
- Analyst Count
- VOXR 0
- LXEO 5
- Target Price
- VOXR N/A
- LXEO $23.80
- AVG Volume (30 Days)
- VOXR 189.2K
- LXEO 521.7K
- Earning Date
- VOXR 05-07-2025
- LXEO 03-18-2025
- Dividend Yield
- VOXR 2.07%
- LXEO N/A
- EPS Growth
- VOXR N/A
- LXEO N/A
- EPS
- VOXR N/A
- LXEO N/A
- Revenue
- VOXR $11,047,763.00
- LXEO N/A
- Revenue This Year
- VOXR $16.51
- LXEO N/A
- Revenue Next Year
- VOXR $4.60
- LXEO N/A
- P/E Ratio
- VOXR N/A
- LXEO N/A
- Revenue Growth
- VOXR N/A
- LXEO N/A
- 52 Week Low
- VOXR $1.83
- LXEO $2.32
- 52 Week High
- VOXR $3.24
- LXEO $19.50
- Technical
- Relative Strength Index (RSI)
- VOXR 48.70
- LXEO 30.13
- Support Level
- VOXR $2.38
- LXEO $2.32
- Resistance Level
- VOXR $2.52
- LXEO $3.38
- Average True Range (ATR)
- VOXR 0.14
- LXEO 0.39
- MACD
- VOXR -0.00
- LXEO -0.04
- Stochastic Oscillator
- VOXR 50.00
- LXEO 15.83
About VOXR Vox Royalty Corp.
Vox Royalty Corp is a returns-focused mining royalty company with a portfolio of over 60 royalties and streams spanning eight jurisdictions. It has built intellectual property, a technically focused transactional team, and a sourcing network which has allowed Vox to target the highest returns on royalty acquisitions in the mining royalty sector.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.